AOD-9604 in Black / African Ancestry Patients: Documented Efficacy Gaps and What the Data Actually Show

What Is AOD-9604 and How Does It Work?

AOD-9604, formally designated HGH fragment 176-191, is a synthetic peptide spanning the C-terminal region of human growth hormone. Heffernan et al. Demonstrated in obese mice that the fragment reduces body fat without the IGF-1-mediated growth effects of full-length GH, suggesting a relatively selective action on adipose tissue [1]. The peptide appears to work by activating beta-3 adrenergic receptors in adipocytes and by modulating the GH receptor axis to tilt energy balance toward lipolysis over lipogenesis.

The Lipolytic Mechanism in Detail

Beta-3 adrenergic receptors (encoded by the ADRB3 gene) sit predominantly on brown and white adipose tissue. When AOD-9604 binds or stimulates downstream signaling through this pathway, hormone-sensitive lipase activity increases and free fatty acid release from stored triglycerides rises. This is not identical to the mechanism of GLP-1 receptor agonists such as semaglutide; AOD-9604 does not suppress appetite through GLP-1 pathways and does not affect insulin secretion directly [1].

GH Receptor Involvement

The GH receptor (GHR) also participates. The exon-3 deletion polymorphism of GHR (GHRd3) alters receptor sensitivity and is present at different frequencies across global populations. Carriers of GHRd3 may respond differently to GH axis peptides including fragments. No trial has yet reported whether GHRd3 carrier status modifies AOD-9604 response in any ethnic group.

The Core Evidence Gap: No Race-Stratified AOD-9604 Trial Data Exists

This is the most clinically significant fact about AOD-9604 in any ethnic population. The peptide reached human trials (Metabolic Pharmaceuticals conducted Phase 2b/3 studies in the early 2000s), but none of those trials published ethnicity-stratified subgroup analyses for Black or African ancestry participants. The absence of data is not evidence of equivalent efficacy; it is evidence of an evidence gap.

What the Preclinical Record Shows

The foundational Heffernan et al. (2001) study used genetically homogeneous obese C57BL/6 mice. Rodent models carry no meaningful analog to human racial pharmacogenomic diversity. Extrapolating those results to any specific human ancestry group requires layering assumption on assumption [1].

A broader search of PubMed and PharmGKB (the NIH-curated pharmacogenomics knowledge base at pharmgkb.org, cross-indexed on ncbi.nlm.nih.gov) returns no variant annotation entries for AOD-9604 in any population as of July 2025. That is not surprising for a peptide that never reached Phase 3 completion or FDA approval, but it means pharmacogenomic guidance must be inferred from pathway-level data rather than drug-specific genotyping studies.

Inferring Risk from Pathway Pharmacogenomics

Because AOD-9604 signals through ADRB3, the Trp64Arg polymorphism (rs4994) is the most relevant known variant. The Arg64 allele is associated with reduced receptor signaling efficiency and has been linked to greater adiposity and poorer response to adrenergic-pathway interventions in several populations. A meta-analysis published in Obesity Reviews found the Arg64 allele frequency is approximately 0.10-0.13 in West African ancestry populations, compared with 0.08-0.10 in European ancestry populations. The difference is modest. Whether it translates to a measurable difference in AOD-9604 lipolytic response has not been tested [see PharmGKB ADRB3 annotation via ncbi.nlm.nih.gov].

Comorbidity Context That Shapes Clinical Risk in Black Patients Considering AOD-9604

Even if AOD-9604 were equally efficacious across ancestries, clinical prescribing cannot occur in a vacuum. Black adults in the United States carry a disproportionate burden of conditions that intersect with the pharmacology of any fat-metabolism peptide.

Hypertension and the Adrenergic Pathway

Approximately 57% of non-Hispanic Black adults have hypertension, the highest rate of any racial group in the US, per CDC NHANES data [2]. AOD-9604 acts on beta-3 adrenergic receptors rather than the beta-1 receptors that govern cardiac output, so direct cardiovascular stimulation is not the primary concern. Still, any adrenergic-axis peptide in a patient already on antihypertensive therapy (particularly beta-blockers) creates a potential interaction worth mapping before prescription.

The well-documented reduced response of Black patients to ACE inhibitors and ARBs compared with calcium-channel blockers or thiazide diuretics (a finding confirmed in the ALLHAT trial, N=33,357) [3] is not directly applicable to AOD-9604 pharmacodynamics, but it illustrates that the adrenergic and renin-angiotensin systems behave differently across ancestries, and that peptide therapies targeting these axes deserve ethnicity-aware clinical thinking.

Chronic Kidney Disease and Peptide Clearance

Black adults develop end-stage kidney disease at approximately three times the rate of white adults, largely driven by APOL1 high-risk genotype variants (G1 and G2 alleles) present in roughly 13% of African Americans [4]. Peptides including AOD-9604 are cleared renally and hepatically. Reduced glomerular filtration rate (GFR) extends the half-life of short peptides, potentially elevating exposure beyond intended dosing assumptions built on predominantly European ancestry trial populations. No AOD-9604 pharmacokinetic study has characterized clearance at varying GFR levels.

G6PD A- Variant: A Commonly Overlooked Safety Consideration

The G6PD A- variant (a glucose-6-phosphate dehydrogenase deficiency allele) is present in an estimated 10-15% of males of sub-Saharan African ancestry [5]. AOD-9604 itself has no documented oxidative stress mechanism that would directly precipitate hemolytic episodes. The clinical relevance here is indirect: many Black patients presenting for peptide therapy at a telehealth clinic will be taking other medications (antimalarials, sulfonamides, nitrofurantoin) that do carry G6PD interaction risk. A thorough medication reconciliation is necessary before any compounded peptide protocol begins.

Dosing Considerations When Standard Protocols Are Built on Non-Diverse Samples

The commonly cited AOD-9604 dosing range in compounded formulations is 300-500 mcg per day via subcutaneous injection, sometimes divided into morning and pre-sleep doses to align with natural GH pulsatility. These numbers come from the Metabolic Pharmaceuticals trials, which enrolled predominantly white Australian and North American subjects.

Weight-Based Versus Fixed Dosing

Body composition differs meaningfully across ancestries. Black individuals, on average, carry greater bone mineral density and lean mass relative to total body weight compared with white individuals of the same BMI, a finding replicated in DXA-based studies [6]. If AOD-9604 acts on adipose tissue specifically, then a fixed 300-500 mcg dose applied to a patient with lower relative fat mass may deliver a different effective adipose-tissue exposure than the same dose in a patient with higher relative fat mass. No pharmacokinetic modeling for AOD-9604 has addressed this.

BMI Thresholds and the "Obese" Entry Criteria Problem

The Metabolic Pharmaceuticals trials used BMI thresholds (>27 or >30) to define eligibility. Standard BMI cut-points were derived from predominantly European cohorts and misclassify cardiometabolic risk in both directions across several ancestries. The AHA and WHO have both acknowledged this limitation [7]. A Black patient with BMI <30 may carry metabolic risk equivalent to a white patient with BMI 32-34, meaning strict BMI-based prescribing criteria may systematically exclude or include patients across racial groups in ways the original trial designs never anticipated.

The HealthRX clinical team has developed an Ethnicity-Aware AOD-9604 Pre-Prescribing Checklist for Black and African ancestry patients that maps six pharmacogenomic, comorbidity, and drug-interaction checkpoints before initiation: (1) GFR-adjusted dosing review, (2) concurrent beta-blocker assessment, (3) G6PD status where medications indicate testing, (4) APOL1 risk allele awareness for patients with proteinuria, (5) DXA-based body composition review when available rather than BMI alone, and (6) blood pressure trending for 4 weeks post-initiation. This checklist is available to HealthRX providers in the clinical portal and is under physician review pending formal publication.

What the GLP-1 Literature Tells Us About the Broader Ethnicity Gap in Metabolic Trials

AOD-9604 has no published race-stratified efficacy data, but the GLP-1 receptor agonist trials provide a cautionary parallel. The STEP-1 trial (N=1,961) of semaglutide 2.4 mg showed 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [8]. However, Black participants comprised only 8% of the STEP-1 sample. A subgroup analysis published in Obesity (2022) found numerically lower weight loss in Black participants (approximately 9.3% vs. 14.9% overall), though the subgroup was underpowered for a definitive conclusion [9].

This pattern, where an entire class of metabolic interventions shows lower effect sizes in Black subgroups, likely reflects a combination of biological factors (receptor polymorphism, adipose tissue distribution), social determinants (dietary context, baseline comorbidity burden), and trial design artifacts (underpowered subgroups, mostly white reference populations). AOD-9604 may or may not replicate this pattern, but the absence of evidence means clinicians have no basis to assume equivalence.

The Endocrine Society Position on Inclusive Trial Design

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states: "Pharmacological agents for obesity management should be evaluated in adequately powered, ethnicity-stratified subgroups to enable race-aware clinical decision-making" [10]. AOD-9604 does not meet this standard. The Endocrine Society's statement applies to approved drugs; AOD-9604 is not FDA-approved, which means even the regulatory expectation of diverse trial representation does not formally apply to it.

Regulatory Status and Its Implications for Black Patients Specifically

In 2023, the FDA finalized its position that AOD-9604 may not be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, citing the lack of approved drug application and insufficient evidence of safety for compounding use [11]. This regulatory decision has downstream effects for all patients seeking AOD-9604, but it carries specific implications for Black patients.

Black Americans are already underserved by mainstream pharmaceutical pipelines. When a compound moves entirely outside regulated channels (unvetted suppliers, inconsistent purity, no standardized dosing), the patients least likely to have access to independent laboratory testing or specialist follow-up are disproportionately harmed by quality failures. Compounded peptide purity data from independent lab analyses (published by platforms including Janoshik and Core Peptides, cited anecdotally in the peptide community) show batch-to-batch variation of 15-30% in some AOD-9604 lots, a range that would be clinically meaningful at a 300 mcg therapeutic dose.

Monitoring Recommendations for Clinicians Treating Black / African Ancestry Patients with AOD-9604

Given the evidence gaps described above, any provider proceeding with AOD-9604 in a Black or African ancestry patient should apply a conservative monitoring protocol.

Baseline Labs

At minimum: comprehensive metabolic panel (CMP), CBC with differential, HbA1c, fasting insulin, lipid panel, uric acid, eGFR, spot urine albumin-to-creatinine ratio (UACR). UACR is specifically recommended because subclinical proteinuria from APOL1-related nephropathy may precede clinical CKD and would change the pharmacokinetic assumptions for peptide clearance.

Follow-Up Intervals

The first follow-up visit should occur at 4 weeks rather than the 8-12 weeks sometimes used in standard peptide protocols. Body composition (ideally DXA; DEXA-derived fat mass percentage is more informative than BMI in this population) should be reassessed at 12 weeks. If no measurable reduction in fat mass is documented at 12 weeks at standard dosing, the clinical picture does not support continuing a compound with no strong ethnic-subgroup efficacy data.

Blood Pressure Trending

Twice-weekly home blood pressure readings for the first 30 days post-initiation. Any increase of >10 mmHg systolic above baseline should prompt hold and review, given the high baseline hypertension prevalence and the theoretical adrenergic pathway interaction.

A Note on Informed Consent in the Absence of Ethnic Subgroup Data

Informed consent for any off-label or research-compound treatment requires disclosing material uncertainties. The absence of ethnicity-stratified efficacy data for AOD-9604 is a material uncertainty for a Black or African ancestry patient. The consent conversation should explicitly cover: (1) that no published trial has evaluated whether AOD-9604 works equally well, better, or worse in Black patients versus the majority-white study populations; (2) that pharmacogenomic differences in the beta-3 adrenergic pathway may affect response; and (3) that the FDA has restricted compounded formulations, affecting product consistency.

The American Society of Clinical Oncology's framework for race-aware oncology consent (while not specific to peptides) offers a useful structural model: acknowledge the gap, quantify the uncertainty where possible, and document that the patient understood the limitation before proceeding [see ASCO policy via pubmed.ncbi.nlm.nih.gov].